NYSE:PFEPharmaceuticals
How Pfizer’s Novavax Matrix-M Deal and GIST Breakthrough (PFE) Has Changed Its Investment Story
In January 2026, Novavax announced a non-exclusive, worldwide license and option agreement granting Pfizer access to its Matrix-M adjuvant technology for vaccine development in up to two infectious disease areas, including an initial field already chosen and a US$30 million upfront payment this quarter.
Together with FDA Breakthrough Therapy Designation for a gastrointestinal stromal tumor regimen combining Pfizer’s Sutent with bezuclastinib, these moves highlight Pfizer’s effort to deepen...